MedPath

Vitamin D Treatment in Patients With Chronic Hepatitis C

Not Applicable
Conditions
Chronic Hepatitis C
Interventions
Drug: Adding vitamin D
Registration Number
NCT00804752
Lead Sponsor
Hillel Yaffe Medical Center
Brief Summary

We hypothesize that patients with Ch.HCV have a low level of vitamin D, and that by raising their vitamin D levels by adding it to their standard treament of Pegylated Interferon and Ribavirin, there will be an increase in their sustained virological response.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Chronic Hepatitis C Genotype 1
Exclusion Criteria
  • Vitamin D intoxication Renal Failure Liver Failure Malignancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Vitamin DAdding vitamin DAn addition of Vitamin D to the standard treatment
Vitamin DVitamin DAn addition of Vitamin D to the standard treatment
Primary Outcome Measures
NameTimeMethod
To increase the sustained virological responseOne year
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hillel Yaffe Medical Center

🇮🇱

Hadera, Israel

Hillel Yaffe Medical Center
🇮🇱Hadera, Israel
Saif Abu-Mouch, MD
Principal Investigator
Jacob Yarchovski, MD
Sub Investigator
Carlos Singer, MD
Sub Investigator
Abed El-Rauf Zeina, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.